Toxin-Based Targeted Therapy for Malignant Brain Tumors
Open Access
- 9 February 2012
- journal article
- review article
- Published by Hindawi Limited in Clinical and Developmental Immunology
- Vol. 2012, 1-15
- https://doi.org/10.1155/2012/480429
Abstract
Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (5P50 NS20023, R37 CA 011898)
This publication has 145 references indexed in Scilit:
- Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsNuclear Medicine and Biology, 2011
- A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancerThe FEBS Journal, 2011
- Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyCancer, 2011
- Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomasNuclear Medicine and Biology, 2010
- Affinity‐matured anti‐glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomasInternational Journal of Cancer, 2010
- Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastomaNeuro-Oncology, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxinsJournal of Controlled Release, 2008
- An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopesProceedings of the National Academy of Sciences, 2008
- Mechanisms and functions of eph and ephrin signallingNature Reviews Molecular Cell Biology, 2002